글로벌 점성 보충 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

점성 보충 시장 분석

점성보충 시장은 골관절염과 효과적인 통증 관리 솔루션이 필요한 기타 관절 질환의 유병률 증가로 인해 상당한 성장을 목격하고 있습니다. 점성보충은 윤활을 개선하고 통증을 줄이며 운동성을 향상시키기 위해 관절에 히알루론산(HA)을 주입하는 것을 포함합니다. 제형 기술의 최근 발전으로 인해 환자의 다양한 요구에 부응하는 보다 효과적이고 오래 지속되는 점성보충 제품이 개발되었습니다. 예를 들어, 새로운 가교 기술과 생물공학적 HA 제품의 도입으로 이러한 주사의 점도와 탄력성이 개선되어 환자 결과가 더 좋아졌습니다. 또한 의료 전문가 사이에서 점성보충의 이점에 대한 인식이 높아짐에 따라 임상 실무에서 도입이 촉진되고 있습니다. 온라인 플랫폼을 포함한 유통 채널의 확대로 이러한 치료법을 환자가 더 쉽게 이용할 수 있게 되었습니다. 또한 점성보충을 다른 치료 방식과 통합하는 복합 요법에 대한 지속적인 연구가 시장 성장을 더욱 촉진할 것으로 예상됩니다. 전반적으로, 관절 보조제 시장은 기술 혁신과 관절 관련 질환에 대한 효과적인 해결책을 찾는 환자 인구의 증가에 힘입어 지속적인 확장이 예상됩니다.

점성 보충 시장 규모

글로벌 점성 보충 시장 규모는 2023년에 15억 3천만 달러로 평가되었으며, 2031년까지 29억 4천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

점성 보충 시장 동향

“ 단일 주사 제형에 대한 선호도 증가”

점액보충 시장은 골관절염 및 효과적인 통증 관리 솔루션을 필요로 하는 기타 관절 질환의 유병률 증가로 인해 상당한 성장을 목격하고 있습니다. 글로벌 점액보충 시장에서 두드러진 추세 중 하나는 기존의 다중 주사 요법보다 단일 주사 제형에 대한 선호도가 높아지는 것입니다. 이러한 변화는 주로 환자의 편의성과 준수에 의해 주도되는데, 단일 주사 제품은 의료 서비스 제공자를 여러 번 방문할 필요성을 줄여주기 때문입니다. 예를 들어, 무릎 골관절염에 대한 단일 주사 히알루론산 치료제인 듀로레인의 도입은 효과와 환자에게 제공하는 편의성으로 인해 인기를 얻었습니다. 또한 정형외과 치료에서 최소 침습적 시술에 대한 강조가 커지면서 이러한 혁신적인 솔루션에 대한 수요가 증가하고 있습니다. 더 많은 환자가 골관절염 및 관절 통증에 대한 효과적이고 편리한 치료법을 추구함에 따라 단일 주사 점액보충 제품의 채택은 글로벌 시장에서 상당한 성장을 촉진하여 환자 만족도와 치료 결과를 향상시킬 것으로 예상됩니다.

보고서 범위 및 점액 보충 시장 세분화       

Viscosupplementation Market Definition

Viscosupplementation is a medical treatment that involves the injection of a gel-like substance, typically hyaluronic acid, into a joint space, most commonly the knee. This procedure is designed to restore the viscosity and elasticity of synovial fluid, which can help lubricate the joint, reduce pain, and improve mobility in individuals suffering from osteoarthritis or joint injuries. By providing cushioning and enhancing joint function, viscosupplementation aims to alleviate discomfort and improve the overall quality of life for patients with degenerative joint conditions.

Viscosupplementation Market Dynamics

Drivers

• Rising Geriatric Population

As the population ages, there is a corresponding rise in the number of elderly patients admitted to hospitals due to serious traumatic injuries. This increase in age-related health issues, particularly knee osteoarthritis, is driving a higher demand for both diagnosis and treatment options. The growing elderly population puts additional pressure on healthcare systems, necessitating more effective care, services, and technologies to prevent and manage knee osteoarthritis, along with related conditions such as sarcopenia, osteoporosis, and osteopenia. Older individuals are particularly susceptible to these ailments, resulting in weakened bones and joints. In these cases, viscosupplementation is increasingly utilized to provide immediate and effective relief for patients. Consequently, as the prevalence of osteoarthritis rises and the need for early diagnosis intensifies, the demand for viscosupplementation treatments is expanding significantly within the global healthcare landscape, making it a crucial market driver.

• Rising Susceptibility to Osteoporosis and Osteoarthritis

Osteoporosis is a bone disease characterized by decreased bone mineral density and mass, along with changes in bone quality or structure, which increases the risk of fractures due to weakened bones. This condition is more prevalent in women, particularly post-menopausal women, who often experience fractures as osteoporosis is a silent disease that typically shows no symptoms. Elderly individuals are also at a higher risk for developing osteoporosis. In contrast, osteoarthritis is a joint disorder marked by inflammation of the joints and surrounding tissues, significantly impairing mobility. These silent conditions lead to weakened bones and joints, resulting in serious consequences such as spinal deformities, fractures, and sudden falls. Consequently, the rising prevalence of osteoporosis and osteoarthritis directly boosts the demand for viscosupplementation treatments aimed at addressing complications arising from these conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive growth in the global viscosupplementation market.

Opportunities

• Safety and Efficacy of Intra-Articular Hyaluronic Acid (IAHA)

Various types of hyaluronic acid injections, commonly referred to as viscosupplementation, are utilized for treating knee osteoarthritis. These injections are derived either from rooster or chicken combs or produced through bacterial fermentation, and they are administered directly into the joint. Intra-articular hyaluronic acid (IAHA) is an FDA-approved treatment for knee osteoarthritis, offering a localized therapeutic option that provides symptomatic relief without the systemic adverse effects commonly associated with intra-articular corticosteroids. Multiple randomized controlled trials (RCTs) and meta-analyses have evaluated the efficacy and safety of IAHA, yielding mixed findings. However, IAHA has been shown to positively impact pain management and improve joint function. In addition, there is growing evidence that multiple courses of IAHA can influence long-term outcomes, such as reducing the reliance on analgesics and delaying the necessity for total knee replacement surgery. This demonstrates a significant market opportunity for viscosupplementation, as the increasing adoption of IAHA in treatment regimens can enhance patient outcomes and expand the market.

• Increasing Investment in Research and Development (R&D)

Investment in research and development (R&D) for viscosupplementation is critical for exploring new applications and enhancing existing products, presenting significant market opportunities. As the understanding of joint health and the mechanisms of osteoarthritis evolves, R&D can facilitate the development of advanced formulations with improved efficacy and reduced side effects. For instance, ongoing research into bioengineered hyaluronic acid derivatives aims to create longer-lasting effects and better integrate with joint tissues, which could significantly improve patient outcomes. In addition, R&D efforts focused on combinations of viscosupplementation with other treatment modalities, such as platelet-rich plasma (PRP) therapy, are showing promising results in clinical trials. These advancements expand the therapeutic potential of viscosupplementation and attract investment and partnerships, ultimately enhancing market reach. Therefore, the commitment to R&D in the viscosupplementation sector represents a vital opportunity for growth and innovation in addressing joint disorders and improving patient care.

Restraints/Challenges

• Lack of Technical Expertise

Finding, attracting, and hiring talent is essential for building a skilled bench of engineers and technicians, but this process poses significant challenges. The manufacturing workforce is aging rapidly, leading to a wave of retirements, while the medical industry faces a shortage of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and those with undergraduate or postgraduate qualifications (engineers) remains high, the supply of qualified individuals is dwindling, particularly for complex procedures such as viscosupplementation that require trained professionals. Moreover, assembling a competent additive manufacturing (AM) workforce goes beyond recruitment; employees must continually update their skills as technology evolves. Many recent engineering graduates lack AM-specific training, making it difficult for employers to find candidates with the necessary expertise. This shortage of technical skills is thus a significant constraint on market growth.

• Stringent Government Regulations

The global commercialization of viscosupplementation by various key market players is contingent upon compliance with regulatory frameworks established in different countries. Pre-market approval processes for medical devices vary significantly across regions, with the U.S. Food, Drug, and Cosmetic Act (FD&C Act) governing medical devices in the United States, while the European Union oversees regulations in Europe. In addition, the rapid evolution of privacy policies and regulations in the Asia-Pacific and EMEA regions, including countries such as India, Russia, China, South Korea, Singapore, Hong Kong, and Australia, further complicates compliance. Viscosupplementation is regulated by a comprehensive structure of laws and guidelines designed to protect patients from potentially harmful treatments. While viscosupplementation serves as a vital intervention for damaged, injured, or infected body parts in cases of osteoarthritis and sports injuries helping to maintain patient mobility any misguidance in its application can jeopardize patient safety and bodily integrity. Therefore, the stringent rules and regulations governing the use of viscosupplementation may pose a significant challenge to market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Viscosupplementation Market Scope

The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

• Animal Origin
• Non-Animal Origin

Age Group

• Geriatric
• Adults

Injection

• Single Injection
• Three Injections
• Five Injections

Molecular Weight

• Intermediate Molecular Weight
• Low Molecular Weight
• High Molecular Weight

End User

• Hospital
• Orthopedic Clinics
• Ambulatory Care Centers
• Others

Distribution Channel

• Direct Tender
• Retail Sales

Viscosupplementation Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is leading the market primarily due to the presence of key players in the industry and its status as the largest consumer market, supported by a high GDP. The U.S. is projected to experience significant growth, driven by advancements in drug treatments and innovative healthcare technologies that enhance patient outcomes. In addition, a robust healthcare infrastructure and substantial investment in research and development further contribute to the region's dominance in the ear and nasal packing market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Viscosupplementation Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Viscosupplementation Market Leaders Operating in the Market Are:

• Anika Therapeutics, Inc. (U.S.)
• SEIKAGAKU CORPORATION (Japan)
• Bioventus (U.S.)
• Fidia Farmaceutici S.P.A (Italy)
• Ferring B.V (Netherlands)
• sanofi-aventis U.S. LLC (U.S.)
• Zimmer Biomet (U.S.)
• OrthogenRx, Inc. (a subsidiary of AVNS) (U.S.)
• APTISSEN (France)
• Johnson & Johnson Services, Inc. (U.S.)
• LG Chem. (South Korea)
• Viatris Inc. (U.S.)
• IBSA Institut Biochimique SA (Switzerland)
• Ortobrand International (U.S.)
• TRB CHEMEDICA SA (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lifecore (a subsidiary of Landec Corporation) (U.S.)
• VIRCHOW BIOTECH (India)
• Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals) (India)

점성 보충 시장의 최신 동향

• 2022년 11월, 관절 보존 헬스케어를 전문으로 하는 유명 기업인 Anika Therapeutics Inc.는 단일 1차 종료점에 초점을 맞춘 3상 임상 시험을 성공적으로 완료했습니다. 이 약물은 심각한 무릎 골관절염을 앓고 있는 개인을 위해 특별히 설계되었습니다. 이 회사는 현재 치료에 대한 FDA 승인을 받고 글로벌 시장에서 사용 허가를 구하는 데 집중하고 있습니다.
• 2022년 6월, 존슨앤존슨은 3상 시험에서 얻은 새로운 결과를 발표했는데, 이 결과에 따르면 해당 약물로 치료받은 환자들은 2년 동안 활동성 건선성 관절염을 관리하면서 더 좋고 일관된 장기적 결과를 경험했습니다.
• 2022년 5월, Fidia Farmaceutici SPA는 스페인에서 출시된 혁신적인 제품 포트폴리오를 통해 히알루론산(HA)의 재생 특성을 성공적으로 활용했습니다. 이 포트폴리오는 다양한 의료 분야에서 조직 복구를 강화하고 치유를 촉진하는 것을 목표로 합니다. HA의 고유한 이점을 활용함으로써 Fidia는 재생 의학 시장의 리더로 자리 매김하고 있습니다.
• 2022년 4월, Kolen Life는 Juniper Biologics와 협력하여 무릎 골관절염에 대한 혁신적인 치료법인 TissueGene-C 저용량을 개발하고 상용화했습니다. 이 치료법은 단일 관절 내 주사로 제공되며 수술적 개입이 필요하지 않습니다.
• 2021년 5월, 오노제약(주)과 세이카가쿠(주)는 관절 기능을 강화하도록 설계된 30mg 관절내 주사제인 JOYCLU를 출시했습니다. 세이카가쿠는 2021년 3월 일본에서 이 제품에 대한 제조 및 마케팅 승인을 받았습니다.

SKU-10709